How Our Immune System Can Help Fight Cancer

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Jeannine Villella DO, Winthrop University Hospital
ClinicalTrials.gov Identifier:
NCT01042847
First received: January 4, 2010
Last updated: December 30, 2016
Last verified: December 2015

January 4, 2010
December 30, 2016
January 2010
February 2015   (Final data collection date for primary outcome measure)
To examine the association of indoleamine 2,3-dioxygenase (IDO) genetic polymorphisms with clinical outcomes of ovarian cancer. [ Time Frame: one year ]
Same as current
Complete list of historical versions of study NCT01042847 on ClinicalTrials.gov Archive Site
To correlate IDO activity with gene polymorphisms by measuring tryptophan/kynurenine ratios in the ascites of epithelial ovarian cancer patients. [ Time Frame: one year ]
Same as current
Not Provided
Not Provided
 
How Our Immune System Can Help Fight Cancer
The Effect of Genetic Polymorphisms in Indoleamine 2, 3-Dioxygenase in Epithelial Ovarian Cancer

There is growing evidence that our immune system can help fight cancer. This has stimulated interest in the development and application of tumor vaccines for several human solid tumors, including epithelial ovarian cancer (EOC). A major obstacle to the development of these vaccines is that there are specialty cells called regulatory T cells that prevent the immune system from attacking all of our organs. These regulatory T cells also prevent our immune system for attacking cancer cells.

Indoleamine 2,3-dioxygenase (IDO), an enzyme that degrades an essential amino acid tryptophan that is necessary for T cells to multiply, however regulatory T cells are less susceptible to low levels of tryptophan, and can still multiply. This allows cancer growth and progression. This may be explained by genetic polymorphisms (changes) in the IDO gene, which may alter its function. Five of these changes in the IDO gene have been described. In this research project, we are asking if you would donate a small piece of your tumor and ascites to see if we can examine your IDO gene in the tumor cells and see if any of these gene changes are present. We hope that this will help us understand how the immune system works in EOC.

We hypothesize that genetic polymorphisms within the IDO gene alter its enzymatic activity and affect the outcome of ovarian cancer patients. These findings have the potential to translate into a method for predicting successful immunotherapy.

Not Provided
Observational
Observational Model: Case-Only
Time Perspective: Prospective
Not Provided
Retention:   Samples With DNA
Description:
surgical tissue ascites fluid
Non-Probability Sample
Patients with histologically confirmed epithelial ovarian cancer (EOC) who have had surgical resection for their disease will be included in this study.
Ovarian Cancer
Not Provided
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
169
February 2015
February 2015   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • females aged 20-90 who are having surgery to confirm epithelial ovarian cancer.

Exclusion Criteria:

  • patients who have a diagnosis of non-epithelial histology.
Sexes Eligible for Study: Female
20 Years to 90 Years   (Adult, Senior)
No
Contact information is only displayed when the study is recruiting subjects
United States
 
 
NCT01042847
09316
No
Not Provided
Not Provided
Not Provided
Jeannine Villella DO, Winthrop University Hospital
Winthrop University Hospital
Not Provided
Principal Investigator: Jeannine A Villella, D.O. Winthrop University Hospital
Winthrop University Hospital
December 2015

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP